Back to top

Image: Bigstock

Agenus Inc.

Read MoreHide Full Article

Agenus’ third-quarter 2015 results were mixed with the company posting wider-than-expected loss but surpassing revenue expectations. Agenus has several collaboration agreements, which not only validate its technology platforms but also provide funds. Agenus received a major boost when the FDA cleared its IND application for AGEN1884 and a second CPM antibody, for which it has a partnership with Incyte. Meanwhile, the company is progressing with the development of Prophage Series vaccine, which is scheduled to enter into a phase III study for newly-diagnosed GBM. However, Agenus is heavily dependent on its partners for the development of its candidates. It has only a few candidates in mid- or late- stages of development. Any unfavorable outcome from the studies may affect shares adversely.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Agenus Inc. (AGEN) - free report >>